The Breakthrough T1D invites applications to develop continuous C-peptide monitoring (CCPM) technologies. The RFA supports early-stage development, preclinical testing, and initial clinical evaluation of continuous C-peptide monitoring (CCPM) technologies. It seeks sensor platforms that can detect physiological C-peptide levels with high sensitivity, specificity, stability, and suitability for real-world, longitudinal use. While continuous monitoring is the
Access Restricted: Members-Only Content. We're sorry, but this content is available exclusively to our subscribed members: